Key result
Endovascular therapy drives ~2.6-fold higher 30-day stroke or death vs. medical therapy in ICAS.
Why the study?
The comparative efficacy and safety of endovascular therapy relative to best medical treatment for symptomatic intracranial atherosclerotic stenosis remain controversial.
Does endovascular therapy reduce the risk of stroke and death compared with best medical treatment in patients with symptomatic intracranial atherosclerotic stenosis?
Meta-Analysis (n=1,534)
Does endovascular therapy reduce the risk of stroke and death compared with best medical treatment in patients with symptomatic intracranial atherosclerotic stenosis?
In patients with symptomatic intracranial atherosclerotic stenosis, endovascular therapy significantly increases 30-day risk of stroke, intracranial hemorrhage, and death without offering any clinical benefit at 1 year compared to best medical treatment.
Answers are grounded in this paper and cite their sources.
Endovascular therapy increases early stroke or death risk; challenges its use and reinforces best medical treatment as standard in intracranial atherosclerotic stenosis.
Background: Endovascular therapy (EVT) has emerged as a promising intervention for symptomatic intracranial atherosclerotic stenosis (ICAS); however, its comparative efficacy and safety relative to best medical treatment (BMT) remain controversial. We aimed to evaluate outcomes after EVT compared with BMT for ICAS. Methods: Electronic databases were systematically searched from inception through March 2026, without restrictions, to retrieve randomized controlled trials (RCTs) comparing EVT versus BMT in patients with ICAS. Pooled risk ratios (RRs) with corresponding 95% confidence intervals (CIs) were estimated using a random-effects model. Results: Seven RCTs comprising 1,534 patients were included, all judged to have a moderate-to-low risk of bias. Compared with BMT, EVT was associated with a significantly higher risk of any stroke or death within 30 days (RR 2.60, 95% CI 1.66-4.09; p<0.0001; I²=0%), all-cause death (RR 3.52, 95% CI 1.04-11.88; p=0.04; I²=0%), all-stroke (RR 2.15, 95% CI 1.25-3.69; p=0.005; I²=0%), and intracranial hemorrhage (RR 3.54, 95% CI 1.31-9.52; p=0.012; I²=14.9%). The composite clinical outcome was also more frequent after EVT (HR 1.32, 95% CI 1.03-1.69; p=0.026). In contrast, the risk of any stroke or death, all-cause death, all-stroke, ischemic stroke, fatal or disabling stroke, and myocardial infarction through 1 year was similar between the two groups. Conclusion: Among patients with ICAS, EVT carried a higher risk of early stroke and death without providing a significant 1-year advantage over BMT.
No takes yet. Share an insight, caveat, or question.
Abdelkader et al. (2026) conducted a meta-analysis in Symptomatic intracranial atherosclerotic stenosis (ICAS) (n=1,534). Endovascular therapy (EVT) vs. Best medical treatment (BMT) was evaluated on Any stroke or death within 30 days (RR 2.60, 95% CI 1.66-4.09, p=<0.0001). Endovascular therapy increased 30-day stroke or death versus best medical treatment in intracranial atherosclerotic stenosis.
Synapse has enriched 10 related papers. Consider them for comparative context: